Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung

Stopped Company discontinued further development of study drug for this indication

Conditions

• Squamous Cell Carcinoma of the Lung

Interventions

• DRUG: Phase I: Glembatumumab Vedotin
• DRUG: Phase II: Glembatumumab Vedotin

Sponsor

PrECOG, LLC.

Collaborators

• [object Object]